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Editorial
Future of allergen-specific immunotherapy
Takeru Ishikawa
On 27-29 January 1997 a workshop regarding allergen-
specific immunotherapy was held at WHO headquarters in
Geneva, Switzerland in order to establish a position paper
which might represent international consensus. A total of
22 participants from 11 countries met to discuss standard-
ization of the concept, therapeutic methods, as well as the
future of immunotherapy. The meeting was co-chaired by
J Bousquet, RF Lockey and H-J Mailing.
At the beginning of the meeting, we discussed the term
'allergen vaccine', which appeared in the title of the
position paper, 'Allergen immunotherapy: Therapeutic
vaccines for allergic diseases'. Despite some reservations
the committee agreed to use the term 'allergen vaccine'.
The idea of the allergen immunotherapy, which was first
tried by Curtis in 1890 on patients with pollenosis, origi-
nated in a 'vaccine' to protect immunologically against
out-coming foreign bodies. Polatino, horse antiserum to
pollen allergen, which was developed by Dunbar in 1903,
really originated from an idea of antiserum vaccine
against microorganisms, and even allergen-specific hypo-
sensitization therapy tried by Noon in 1911,1 was also
based on the concept of vaccination against pollen-toxins.
The purpose of immunotherapy should be the primary or
secondary prevention of hyperreactivity by the induction of
hypo-responsiveness to the allergenic substances, which
are causative to IgE antibody production. Therefore, there
may be some differences in the concept between immuno-
therapy to allergic diseases and vaccination. However, a
mechanism producing clinical effectiveness has not con-
clusively been clarified yet. Each of the theories proposed
by successive researchers, such as theories of blocking
antibodies, suppressor T cells, shift to Th1 from Th2
dominance and tolerance/anergy, are still considerable
candidates for explaining immunological effectiveness.
From a practical point of view, standardization of the
allergens, efficacy, risk and indication of immunotherapy
were discussed and revised several times, and finally a
consensus was reached by the co-chairpersons on the
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proposed draft, which will be published in the near future.
Among them, other routes for the application of allergens
besides subcutaneous injection,2-4 such as oral, sub-
lingual, nasal and bronchial, drew my attention. Although
many reports were tabled concerning this, more extensive
studies may be needed to establish the methodology
because this form of therapy may result in discomfort and
inconvenience given the frequent injections. In addition,
the direct application of allergen, either native or modi-
fied, to the local tissue may be more promising for
controlling mucosal immune response.
In the last section of the meeting, several future strate-
gies for immunotherapy were proposed, such as active
immunotherapy using nonanaphylactic allergens; allergen-
fragments or peptides; IgE-binding haptens of major
allergens for passive saturation of effector cells; plasmid
DNA immunization; allergen-specific antibodies and
antibody fragments for passive therapy in the allergic
effector organs; and immunotherapy with humanized
anti-lgE monoclonal antibodies or IgE-mimotopes.
I would like to take the opportunity to comment on
allergen peptides for active immunotherapy. The recent
development of chemistry has accelerated study on the
analysis of responsible allergenic epitopes in peptide
levels. Furthermore, a mechanism of conversation be-
tween T cell receptor (TCR) and antigen presenting cells
(APC) expressing antigen epitope cognate with MHC
molecule, HLA in humans, has now been clarified. In
addition, results of the studies informed us of an important
fact: that the activated T cell, through the specific antigen
stimulation, releases various cytokines which modulate the
immune reaction. The recognition system is common to
most of immune reactions including autoimmune, cancer
immune, as well as immune response to out-coming anti-
genic substances such as micro-organisms, allergens
and so on. Regarding IgE mediated allergies, it has been
understood that HLA class II is essential to specific recog-
nition of TCR as a restriction molecule. Also, the HLA class
II allergen peptide complexes stimulate Th2, releasing
characteristic cytokines, such as IL-3, 4, 5, 6, 10, 13 and
so on. It has been generally accepted that the allergic
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target tissues are dominantly infiltrated by activated Th2.
Th1, on the other hand, is characterized by released
cytokines, such as IL-2, IL-3, IFN-y, TNF-~, TNF-a, GM-
CSF and so on. In addition, as is well known, IFN-y inhibits
the production of IgG 1 and IgE elicited by IL-4. Therefore,
in this sense the purpose of allergen immunotherapy may
be the induction of a Th1 dominant state, shifted from Th2
in the allergic targets.
Sloan-Lancaster et cl.? and Briner et ol." have docu-
mented that antigen specific T-cell anergy could be induced
by an injection of antigen under a certain condition in mice.
Furthermore, clinical trials have already been undertaken
using synthetic allergen peptides derived from cat dander
allergen Fel d 1 in the USA,? which might be based theor-
etically on the induction of allergen specific T cell anergy. In
this sense, the induction of anergy or tolerance to a specific
allergen must be an aim of the immunotherapy.
Considering these two theories, there is some confusion
regarding which allergen epitope should be used for
the immunotherapy: responsible epitope to stimulate Th1
releasing IFN-y,8 or responsible epitope to stimulate Th2
inducing T cell anergy.
There have been reports of established cloned or lined
T cells reacting to various allergen peptides derived from
dermatophagoides,9 rcqweed.!? cat donder.!' rye qross.'?
timothy;':' birch pollen.!" Japanese cedar pollen 15 and so
on. Their cytokine production profile indicated that the
clones or lines were mostly Th2 dominant. However, it has
often been observed that multiple epitopes in allergen
peptides react to T cells from one individual, and that the
reacting epitope is different from patient to patient. We
also confirmed that T eel/lines from 12 patients allergic to
Japanese cedar pollen reacted to various overlapping
peptides derived from the purified Japanese cedar pollen
allergen, Cry j1.16 In addition, cytokine release profiles
found in this experiment indicated that the one definite
peptide did not always stimulate the same type of T cell,
either Th1 or Th2. For instance, one peptide activated Th2
from one individual and released dominantly IL-4;
however, the same peptide proliferated Th1 from another
individual and released IFN-y. Therefore, it can be said
that multiple T cell epitopes in each allergen may com-
plicate immunotherapy, as has been pointed out by van
Neerven. 11 As seen in the clinical trial of immunotherapy
to Fel d 1 sensitive patients, multiple peptides may have to
be used as the therapeutic allergens for more than 80%of
patients treated. However, it remains debatable whether
Th1 or Th2 should be targeted.
Thus, peptides as a T cell epitope have several prac-
tical merits in immunotherapy; nonanaphylactic allergen,
capacity to use a large amount of antigen, and high
accuracy of antigen standardization. These merits may
provide the variety of routes for application of peptide
allergens, namely oral, sublingual, nasal or bronchial as
well as intradermal injection, mentioned above. How-
ever, study on drug carrier technology may be important
in facilitating more effective absorption of peptide mole-
cules from the airway or alimentary mucosa.
Therefore, further basic and practical studies still need
to be undertaken in order to establish the exact effect
of the peptide immunotherapy, as well as to establish
methods of inducing hyporesponsiveness against allergens
while avoiding any side-effects.
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